Related Experiment Video
Updated: Feb 4, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls
S Shahzad Mustafa1,2, Deep Shah1, Jonathan Bress1,3
1a Department of Medicine , Rochester Regional Health , Rochester , NY , USA.
Abstract:
Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent response, it is recommended in patients with multiple myeloma. This study compares the initial response to PCV13 and durability of the response at 6 months in patients with multiple myeloma versus normal controls. Seven patients with multiple myeloma and 18 control patients were enrolled in the study. Streptococcal pneumonia serotype IgG titers were drawn at baseline, day 30, and day 180 after MM patients and controls received PCV13. Although vaccination with PCV13 produced a similar initial response in patients with multiple myeloma compared to control subjects, the duration of response may have waned in patients with multiple myeloma as compared to control subjects.
Insights
Multiple myeloma patients show a similar initial immune response to the pneumococcal conjugate vaccine (PCV13) compared to healthy individuals. However, the vaccine
Area of Science:
- Immunology
- Vaccinology
- Hematology
Background:
- Infections pose significant risks for multiple myeloma (MM) patients due to impaired immune function.
- Humoral dysfunction in MM patients leads to inadequate responses to vaccines like the pneumococcal polysaccharide vaccine (PPV23).
- The pneumococcal conjugate vaccine (PCV13), which induces a T-cell dependent immune response, is recommended for MM patients.
Purpose of the Study:
- To compare the initial immune response to PCV13 in multiple myeloma patients versus healthy controls.
- To assess the durability of the immune response to PCV13 at six months post-vaccination in both groups.
Main Methods:
- Seven patients with multiple myeloma and 18 healthy controls were enrolled.
- Streptococcal pneumonia serotype IgG titers were measured at baseline, day 30, and day 180 after PCV13 vaccination.
Main Results:
- PCV13 vaccination elicited a comparable initial IgG titer response in multiple myeloma patients and control subjects.
- The duration of the immune response to PCV13 appeared to diminish more rapidly in multiple myeloma patients compared to controls by day 180.
Conclusions:
- While PCV13 provides an initial immune response in multiple myeloma patients, its long-term effectiveness may be compromised.
- Further research is needed to understand and potentially improve the durability of PCV13 responses in immunocompromised individuals with multiple myeloma.
Related Concept Videos
Vaccinations
Bioavailability Study Design: Healthy Subjects Versus Patients
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Multiple Allele Traits
Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...

